MRNA Company Profile and Key Details
Moderna, Inc.
MRNA Stock Price Chart
Stock Price Today
Moderna, Inc. (MRNA) stock surged +3.35%, trading at $32.99 on NASDAQ, up from the previous close of $31.92. The stock opened at $30.55, fluctuating between $29.25 and $33.91 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 5600 |
| Beta | 1.69 |
| Sales or Revenue | $6.75B |
| 5Y Sales Change% | 10.869% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Moderna, Inc. (NASDAQ: MRNA) stock price is $32.99 in the last trading session. During the trading session, MRNA stock reached the peak price of $33.91 while $29.25 was the lowest point it dropped to. The percentage change in MRNA stock occurred in the recent session was 3.35% while the dollar amount for the price change in MRNA stock was $1.07.
The NASDAQ listed MRNA is part of Biotechnology industry that operates in the broader Healthcare sector. Moderna, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Stephane Bancel
Chief Executive Officer & Director
Mr. Juan Andres
Pres of Strategic Partnerships & Enterprise Expansion
Dr. Jerh Collins Ph.D.
Chief Technical Operations & Quality Officer
Dr. John V. W. Reynders Ph.D.
Chief Information Officer
Mr. James M. Mock
Chief Financial Officer
Ms. Lavina Talukdar CFA
Senior Vice President & Head of Investor Relations
Dr. Stephen Hoge M.D.
Pres
Mr. Brad Miller
Chief Information Officer
Dr. Melissa J. Moore Ph.D.
Chief Scientific Officer & Member of Scientific Advisory Board
Ms. Arpa Garay
Chief Commercial Officer
Colleen Hussey
Senior Director of Corporation Communications
Ms. Shannon Thyme Klinger
Chief Legal Officer & Corporation Sec.
MRNA's closing price is 12.77% higher than its 52-week low of $29.25 where as its distance from 52-week high of $170.47 is -80.65%.
Number of MRNA employees currently stands at 5,600.
Official Website of MRNA is: https://www.modernatx.com
MRNA could be contacted at phone 617 714 6500 and can also be accessed through its website. MRNA operates from 200 Technology Square, Cambridge, MA 02139, United States.
MRNA stock volume for the day was 25.13M shares. The average number of MRNA shares traded daily for last 3 months was 10.59M.
The market value of MRNA currently stands at $12.70B with its latest stock price at $32.99 and 384.82M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com